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CLINICAL OBSERVATIONS, INTERVENTION, AND THERAPEUTIC TRIALS
Gene-Gene and Gene-Environment Interactions Determine Risk of Thrombosis
in Families With Inherited Antithrombin Deficiency
By H.H. van Boven, J.P. Vandenbroucke, E. Briet, and F.R. Rosendaal
To analyze inherited antithrombin deficiency äs a risk factor
for venous thromboembolism in various conditions with
regard to the pres.. ~ ~e or absence of additional genetic or
acquired risk factors, we compared 48 antithrombin-defi-
cient individuals with 44 nondeficient individuals of 14
selected families with inherited antithrombin deficiency. The
incidence of venous thromboembolism for antithrombin
deficient individuals was 20 times higher than among non-
deficient individuals (1.1% v 0.05% per year). At the age of 50
years, greater than 50% of antithrombin-def icient individuals
had experienced thrombosis compared with 5% of nondefi-
cient individuals. Additional genetic risk factors, Factor V
Leiden and PT20210A, were found in more than half of these
selected families. The effect of exposure to 2 genetic defects
was a 5-fold increased incidence (4.6% per year; 95% confi-
dence interval [Cl], 1.9% to 11.1%). Acquired risk factors
were often present, determining the onset of thrombosis.
The incidence among those with exposure to antithrombin
deficiency and an acquired risk factor was increased 20-fold
(20.3% per year; 95% Cl, 12.0% to 34.3%). In conclusion, in
these thrombophilia families, the genetic and environmental
factors interact to bring about venous thrombosis. Inherited
antithrombin deficiency proves to be a prominent risk factor
for venous thromboembolism. The increased risks among
those with exposure to acquired risk factors should be
considered and adequate prophylactic anticoagulant therapy
in high-risk situations seems indicated in selected families
with inherited antithrombin deficiency.
© 1999 by The American Society of Hematology.
SINGE THE ASSOCIATION of familial antithrombin defi-ciency and venous thromboembolism was described by
Egeberg in 1965,1 many single cases and families have been
reported in the literature. Based on these reports, the clinical
manifestations of inherited antithrombin deficiency have been
assessed in reviews.2"5 The frequency of a history of venous
thromboembolism was estimated to be 51% among deficient
individuals in one of these reviews.5 This risk of venous
thrombosis should be viewed äs that among highly thrombosis-
prone families, ie, families who were diagnosed and selected to
be reported.
An extensive study of one very large family was,performed
by Demers et al.5 The risk of venous thromboembolism in this
selected family was less than 20% (6/31) in deficient family
members; 0 of 36 nondeficient family members had had a
thrombotic event.5 In a population-based case control study, the
association of antithrombin deficiency and venous thromboem-
bolism was assessed in unselected outpatients with venous
thrombosis. Because of the rarity of the defect, only a small
number of 5 patients and l control with antithrombin deficiency
were diagnosed in this study (Leiden Thrombophilia Study).6 In
this setting, the relative risk for thrombosis was 5.0 (95%
confidence interval [Cl], 0.7 to 34).6 The only family study of
pedigrees not selected on a high frequency of venous thrombo-
embolism has been performed among healthy blood donors.7 In
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blood donors diagnosed with an inherited deficiency of anti-
thrombin or protein C and their relatives, the thrombosis rate
was low. Only 4% (2/51) of individuals with antithrombin
deficiency had experienced venous thrombosis and l subject
experienced a recurrence.7 One might argue that here there is
soma-selection on absence of disease.
Apparently, differences in selection lead to very different
risks between relatives of healthy carriers, relatives of consecu-
tive outpatients, and relatives of selected families with familial
thrombophilia (the latter display the highest risk).8 These
differences are likely not just to be stochastic phenomena, but to
have a biological basis and to be the result of the simultaneous
presence, or absence, of other risk factors. It is becoming
increasingly clear that thrombosis is a multicausal disease and
that several factors, acquired and genetic, interact to bring about
thrombosis.9"12
Because clinicians will have to offer guidelines to individuals
from families with thrombophilia, in which the risk appears
highest, knowledge of factors contributing to the risk is
essential. To date, no risk estimates for thrombosis in antithrom-
bin deficiency based on a large number of families were
available. Therefore, we set out to determine the risk of
thrombosis in families with thrombophilia and antithrombin
deficiency to assess the interaction with other risk factors,
genetic and acquired.
MATERIALS AND METHODS
Participants of this family study were identified through family trees
of 15 probands diagnosed with type I antithrombin deficiency. The
parents, siblings, and children of the proband were invited to partici-
pate, äs well äs siblings of the affected parent and the children of
affected siblings. Ten of the 15 probands had been referred for tests
because of unexplained thrombosis and recurrent thrombosis, thrombo-
sis occurring at a relatively young age, or a family history for
thrombosis. Three probands were registered in our hospital with
familial thrombophilia due to antithrombin deficiency. We included l
proband referred because of high doses of heparin for treatment of
recurrent thrombotic episodes and therefore screened. One proband had
been referred to our center because of a positive family history;
simultaneously, he participated and was identified again, independently,
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in a population-based patient control study, the Leiden Thrombophilia
Study (LETS).6 Two probands were found to have a common ancestor.
Each family member was interviewed, and a detailed history of
thromboembolic diseases was obtained by the same physician (H.H.v.B.)
using a standardized questionnaire. Family members were questioned
specifically about history of venous thromboembolism, ie, deep venous
thrombosis and pulmonary embolism. If an individual reported such a
problem, information about the method of diagnosis was obtained äs
well äs clinical risk factors for thrombosis at the time of or preceding the
event. Risk factors were defined a priori äs surgery, hospitalization,
immobilization, major trauma, plaster casts, pregnancy, postpartum
state, and use of oral contraceptives. The criteria used for the diagnosis
of previous venous thromboembolism were hospitalization or treat-
ment. The clinical diagnosis of the physician was confirmed with
objective diagnostic techniques in 71% of the first venous thromboem-
bolic event of the relatives.
Venepuncture was performed in each participant. Blood samples
were collected from the antecubital vein in 1/10 vol of 0.11 mmol/L
trisodium citrate. Plasma was prepared by centrifugätjon for 10 minutes
at 2,000g at 10°C and stored at -70°C until use. Antithrombin antigen
concentration was measured by immunoelectropheresis according to the
method of Laurell.13 Amidolytic heparin cofactor assays (Chromogenix,
Mölndal, Sweden) were used for antithrombin activity measurement.
Genomic DNA was isolated from blood leukocytes by Standard
methods. DNA analysis in 9 of the 14 families had elucidated different
defects in the antithrombin gene in 7 families.14 Genetic analysis for the
prothrombin 20210 A allele (PT20210A) and Factor V Leiden (FVL)
was performed äs described previously.15·16 Available DNA samples of
12 families had been screened in a collaborate study described
elsewhere.12
The occurrence of venous thrombosis was assessed for antithrombin-
deficient subjects and nondeficient subjects. In all analyses of relative
risks and risk factors for thrombosis, the probands were excluded to
eliminate bias. Mediän age of onset and thrombosis-free survival curves
were constructed according to the Kaplan and Meier method. To
compare the 2 curves, we used the logrank rest, resulting irua χ2
distribution with l degree of freedom. Confidence intervals for the
thrombosis-free survival rates were calculated based on a binomial
distribution.
The incidence of first thrombotic events in antithrombin-deficient
subjects and nondeflcient subjects was calculated by counting patient-
years of observation and dividing the number of events in each group by
the sum of observation-years of all the individuals in the group.
Similarly, incidence rates were calculated äs the number of thromboses
in the years that surgery, immobilization (including hospital admissions,
plaster casts, and immobilization longer than 2 weeks), pregnancy, and
the postpartum period took place. The time window was l year, and
incidence rate ratios were calculated äs the incidence rate in l year over
the incidence rate in all other years. CIs for incidences and incidence
rate ratios were calculated by the assumption of a Poisson distribution.
Multivariate analysis was performed using the Poisson method for
aggregate data. With multivariate analysis, it is possible to determine
the effect of one variable, while the other variables are adjusted for.
RESULTS
Diagnosis and thrombotic events (relatives only). In all 14
families affected, individuals had antithrombin activity and
antigen levels less than 80 U/mL (type I antithrombin defi-
ciency). Of 107 eligible family members, 90 individuals (84%)
participated: 5 nonrespondents lived abroad and 3 subjects were
in poor health; 6 asymptomatic individuals, of whom 4 had been
tested äs nondeficient before, were not interested in further
investigations and 3 family members could not be contacted
because the proband had no contacts. In total, 46 individuals
proved to be antithrombin-deficient (19 men and 27 women;
average age, 43 years; age ränge, 15 to 88 years); 44 individuals
were normal (23 men and 21 women; average age, 44 years; age
ränge, 18 to 86 years). Before this study, the diagnosis of
antithrombin deficiency was known to 67% of all participants.
Of 46 antithrombin-deficient individuals, 18 subjects had
experienced l or more venous thromboembolic events. The first
clinical manifestation was mostly deep venous thrombosis of
the legs (12/18); l individual presented with Symptoms of
pulmonary embolism, whereas 5 individuals presented with
manifestations of pulmonary embolism and deep venous throm-
bosis. One of 44 nondeficient individuals had experienced
venous thromboembolism.
Precipitating risk factors. Only 2 first episodes (2/18)
occurred apparently spontaneously. Before 16 first thromboem-
bolic episodes, l or 2 of the following risk factors were present:
postpartum period (n = 4), surgery (n = 4), immobilization
(n = 1), plaster cast (n = 2), hospital admission (n = 1), oral
contraceptive use (n = 2), long travel by air (n = 3), and FVL or
PT20210A (n = 5). The l nondeficient individual who had
experienced venous thrombosis had had recent surgery and
proved to be a camer of FVL.
Overall, there were no differences in exposure to predispos-
ing acquired risk factors between antithrombin-deficient indi-
viduals and normal individuals (surgery/trauma, immobilization
and for women oral contraceptive use, pregnancy, and child-
birth). Adäitional genetic factors, FVL and PT20210A, were
found in 7 of the 14 families.
Risk of venous thromboembolism. The median age of onset
was 27 years (ränge, 16 to 68 years) for antithrombin-deficient
individuals (the age of onset was 42 years of age for the
symptomatic individual without antithrombin deficiency). Nota-
bly, the median age of onset for carriers of 2 defects was 17
years (ränge, 16 to 25 years). According to Kaplan and Meier
survival analysis, the median thrombosis-free survival for
antithrombin-deficient individuals was 48 years (Fig 1). Over-
antitnrombin deficient individuals
10 20 30 40 50 60 70 80 90 100
Age (years)
Fig 1. Venous thrombosis-free survival curve in antithrombin-
deficient individuals and nondeficient individuals (probands ex-
cluded). Probability of freedom from venous thrombotic events is
presented. Steps in curves indicate events; short vertical lines indi-
cate censoring.
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all, men more often experienced venous thromboembolism than
women: 9 of 19 men (47%; median age of onset, 27 years;
ränge, 16 to 48 years), whereas 9 of 27 women were symptom-
atic (33%; median age of onset, 26 years; ränge, 16 to 68 years).
The incidence of (first) thrombotic event was 1.1% per year
(95% CI, 0.7% to 1.8%) in the antithrombin-deficient individu-
als, which is more than 20 times greater than among nondefi-
cient individuals (0.05% per year; 95% CI, 0.01% to 0.4%). The
incidence of first thrombotic events was equal in men and
women up to 25 years of age (0.7% per year in men v 0.6% per
year in women); after 25 years of age, incidence was twice äs
high in men äs in women (at 26 to 45 years of age, 3.0% per year
in men v l .7% per year in women; at >46 years of age, 2.2% per
year in men v l .4% per year in women).
Interaction with other riskfactors. We compared the annual
incidence of venous thromboembolism in relatives with expo-
sure to other genetic and acquired risk factors. The risk among
antithrombin-deficient subjects exposed to surgery (12.7% per
year; 95% CI, 5.7% to 28.4%) was much larger than the
increased risk of antithrombin deficiency (0.8% per year; 95%
CI, 0.4% to 1.4%) or surgery (1.6% per year; 95% CI, 0.2% to
11.3%) separately. Table l shows that, overall, the incidence
rates were less than 1% per year for individuals exposed to
inherited antithrombin deficiency only. Among those with
exposure to 2 genetic defects, the incidence rate increased to
4.6% per year (95% CI, 1.9% to 11.1%). Combined exposure to
antithrombin deficiency and an acquired risk Situation led to
even higher incidence rates of 20.3% in the year of the risk
event (95% CI, 12.0% to 34.3%).
For women, exposure to pregnancy, the postpartum period,
and use of oral contraceptives were analyzed separately (women
only). Use of oral contraceptives by antithrombin-deficient
women was associated with an incidence rate of 4.1% per year
(95% CI, 1.0% to 16.3%); the postpartum period conferred the
highest risk for women (incidence rate of 14.3% per year; 95%
CI, 1.0% to 16.3%). When we looked at pregnancies and
Table 1. Incidences of Venous Thromboembolism: Exposure
to Inherited Antithrombin Deficiency and the Effect of Acquired
or Genetic Risk Factors (Men and Women, Univariate)


























































'Surgery, trauma, plaster cast, hospital admittance, immobilization
more than 2 weeks before thrombosis. A time window of 1 year after
the acquired risk Situation was used.
tEpisodes of venous thromboembolism (VT), incidence rates per
100 patient years with 95% confidence intervals.
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*0ne woman had 3 missed abortions.
tProphyiactic anticoagulant therapy was usedduring7 pregnancies
and 10 postpartum periods of antitHrombin-deficient women and
during 2 postpartum periods of nondeficient women.
ΦΟιΐέ" woman suffered recurrentthrombosis in hersecond andthird
pregnancy.
§Four episodes were first events and 4 episodes were recurrences
of thromboemboiic events.
postpartum periods in hitherto asymptomatic women without
anticoagulation prophylaxis, no pregnancies (0/28) but 15% of
postpartum periods (4/27) were complicated by venous throm-
boembolism (Table 2). During pregnancy, only l antithrombin-
deficient woman developed recurrences of venous thrombosis
(twice, in 2 pregnancies). Pregnancies and postpartum periods
of symptomatic antithrombin-deficient women, without antico-
agulant prophylaxis, were complicated frequently by venous
thromboembolism, ie, 20% (2/10 pregnancies) and 50% (4/8
postpartum periods), respectively (Table 2).
Multivariate analysis. The incidence rate ratios computed
with multivariatel-taalysis by Poisson analysis are listed in Table
3. For each factor, the relative risk is shown compared with the
absence of that factor, which is adjusted for all other variables.
Table 3. Adjusted Incidence Rate Ratios for Potential Genetic and




Antithrombin deficiency 25.9 (3.1-216)
20210Aallele 4.6(0.9-21.4)
FVL 7.2(1.9-27.6)
Surgery, immobilizationt 10.9 (3.9-29.8)
Pregnancy and postpartum state* 48.6 (9.1-260.7)
Use of oral anticonceptives* 5.3 (0.6-48.1)
*The incidence rate ratios are adjusted for age, calendar time, and
sex.
tSurgery, trauma, plaster cast, hospital admittance, immobilization
more than 2 weeks before thrombosis.
tWomen only in regression analysis.
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In these families, the most prominent risk factor is antithrombin
deficiency, increasing the incidence 26-fold in multivariate
analysis. Other genetic risk factors (FVL and PT20210A) were
strong risk factors, too, with relative risks of 5 to 7. Well-
established acquired risk factors, such äs surgery and immobili-
zation, were associated with a relative risk of 10. For women,
the postpartum state accounted for the highest relative risk
when recalculated to an annual risk (Table 3). These results
were almost comparable to our univariate analysis; due to small
numbers, unfortunately, the estimates for interaction between
risk factors could not be calculated.
Thrombotic disease in the probands. In all prior analyses,
the probands were excluded to avoid ascertainment bias. In
probands, severity of disease was indeed impressive: the 14
probands of these families, 9 men and 5 women (average age,
51 years; age ränge, 24 to 77 years) had all suffered recurrent
thromboembolism. The median age of onset was 33 years of age
(age ränge, 19 to 55 years). One proband presented spontane-
ously with mesenterial thrombosis, and l proband developed
mesenterial thrombosis äs a recurrence after surgery. The most
frequent clinical presentation was deep venous thrombosis of
the leg with pulmonary embolism.
Six of 14 episodes of onset (43%) and 9 of 19 recurrences
(47%) had occurred in the absence of an additional precipitating
risk factor. An additional genetic defect, FVL, was identified in
l female proband only. Acquired risk factors such äs surgery
and immobilization were the precipitating risk factor in men.
Among the female probands, pregnancy, postpartum period,
and oral contraceptive use were present before two thirds of all
episodes (onset and recurrences). Four female probands had
developed venous thromboembolism within 3 months after first
prescription of oral contraceptives.
DISCUSSION
Venous thromboembolism is a multicausal disorder. Age,
surgery, immobilization, oral contraceptive use, and postpartum
state are well-known predisposing factors for venous thrombo-
embolism. In thrombophilia families, the genetic and environ-
mental factors interact to bring about venous thrombosis. This
family study showed a 20-fold increased risk for venous
thromboembolism in antithrombin-deficient individuals versus
nondeficient individuals. The risks became extremely high in
the simultaneous presence of other genetic or environmental
risk factors.
Acquired and genetic risk factors were often present simulta-
neously at the onset of thrombosis. The annual incidence
increased 10- to 20-fold among individuals who had been
exposed to an acquired risk factor and inherited antithrombin.
The incidence rate was less than l % per year among individuals
exposed to inherited antithrombin deficiency only. Thus, envi-
ronmental risk factors lead to interaction äs the effect of
antithrombin deficiency and environmental risk factors together
was greater than the sum of the effect of each of these risk
factors separately (Table 1). Similarly, a 5-fold increase of the
annual incidence was found due to gene-gene interactions.
Summarized, both gene-environmental interactions and gene-
gene interactions play an important role in the onset of venous
thromboembolism in inherited antithrombin deficiency.
Most families in this study were referred to our center,
therefore representing high-risk families. Overall, our risk
estimates should be viewed äs the risks for antithrombin-
deficient individuals, who are thrombosis-prone and referred for
thrombophilia work-up. Families with inherited antithrombin
deficiency selected differently may very well display different,
ie, lower, risks.
When thrombophilia is viewed äs a multicausal disorder,
highly thrombosis-prone families are identified, because com-
mon genetic defects are present simultaneously in those fami-
lies. In this study, DNA analysis showed the presence of 2
common genetic factors in 7 of the 14 families with inherited
antithrombin deficiency. When thrombosis occurred in a patient
at a young age, an additional genetic defect, the FVL or
PT20210A, was most often present. In the other individuals,
interaction with environmental risk factors had led to high risks.
Although these risk factors are not genetic, they may, even
when present comcidentally, make a family stand out that is
then recognized äs thrombophilic.
It is believed that antithrombin deficiency confers a higher
risk than protein C, protein S, and FVL. Again, a comparison
between families seems only justified when the investigated
families are selected under similar criteria. Lensen et al8 showed
that, when uniform selection criteria were applied, no differ-
ences in median age of onset were observed between selected
families with protein C deficiency or activated protein C (APC)
resistance^The selection criteria used in the study by Lensen et
al8 were similar to the criteria of our selection of families with
inherited antithrombin deficiency. After making a comparison,
the median ages of onset in our antithrombin-deficient families
approximated the median ages of onset of families with protein
C deficiency and APC resistance. The median age of onset was
26 years (ränge, 16 to 50 years) for probands and 35 years
(ränge, 17 to 65 years) for relatives with protein C deficiency; in
high-risk families with APC resistance, the median age of onset
was, respectively, 29.5 years (ränge, 21 to 46 years) and 29
years (ränge, 16 to 63 years); in our families, the median age of
onset was, respectively, 33 years (ränge, 19 to 55 years) and 27
years (ränge, 16 to 68 years). The median ages of onset in
protein C deficiency, APC resistance, and antithrombin defi-
ciency suggest that differences between thrombophilia disor-
ders may be minor compared with the effect of selection.
We also compared our data with a study of families with
protein C deficiency, in which the applied selection criteria were
again quite similar.17 The risk estimates comprised a 9 times
higher incidence of venous thrombosis among protein C-
deficient individuals than among nondeficient individuals (crude
odds ratio, 9.2; 95% CI, 5 to 16.8); the age-related incidence
rates were a little lower, but the incidence rates after surgery
(incidence rate ratio, 9.2; 95% CI, 3.5 to 24.9) differed little
from the incidence rates in the antithrombin-deficient families.
We suggest that antithrombin deficiency is not different from
protein C deficiency or other thrombophilia disorders: the risk
of antithrombin deficiency is often enhanced simultaneously by
other factors, both environmental and genetic. For that reason
too, the risk of inherited antithrombin deficiency is unlikely to
be much higher than for the other deficiencies, because, in that
case, there would be no or less need for additional enhancing
risk factors.
For this study, we only included the thromboembolic epi-
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sodes that required hospitalization and treatment with anticoagu-
lant therapy. The detailed history of thromboembolic diseases
was obtained using a standardized questionnaire, which was
proven to be a valuable tool for the diagnosis of personal past
episodes of venous thromboembolism.18 The majority of the
clinically suspected first episodes of venous thromboembolism
(71%) were confirmed by reliable objective tests. It seems likely
therefore that our data are accurate and not overestimated. The
probands were rightly excluded from the analysis because of
ascertainment bias. Their clinical manifestations pointed to a
higher (rscurrence) risk of venous thromboembolism. It was
remarkable that we observed almost no additional genetic
defects in the probands. Given their impressive thrombotic
histories. additional yet unknown factors seem likely.
We studied the highly thrombosis-prone and referred fami-
lies. The heterogeneity of the molecular basis of antithrombin
deficiency in these families was in accordance with reported
mutations in other families.14 In the absence of other risk
factors, we found that the annual incidence was less than 1% per
year. This implies that, even in the worst case, lifelong
prophylactic therapy cannot be justified, because higher annual
risks of bleeding complications have been consistently re-
ported.19·20 In contrast, with gene-environmental interaction,
incidence rates in high-risk situations exceeded the reported
risks of bleeding complications. The use of prophylaxis has to
be cons idered carefully but seems indicated äs short-term
prophylactic anticoagulant therapy in all high-risk situations.
The postpartum period showed to be the most prominent
acquired risk factor for onset of venous thromboembolism in
women. The risk was also greater in the puerperium than during
pregnancy (Table 3). Based on these data, adequate prophylac-
tic anticoagulant therapy for asymptomatic pregnarlt women
may be confined to the postpartum state only.
In conclusion, venous thromboembolism in inherited anti-
thrombin deficiency proved to be multicausal. Inherited anti-
thrombin deficiency was a strong risk factor. In the presence of
other precipitating risk factors, interactive effects strongly
determined the risk of thrombosis for an individual. In selected
families with young symptomatic family members, additional
genetic factors should be assessed. The risks of acquired risk
factors should be considered and adequate prophylactic antico-
agulant therapy seems indicated only during high-risk situa-
tions. Further study is needed to assess whether similar risks are
found in unselected families.
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